Melanoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are 18 years of age or older
- You have been diagnosed with advanced melanoma (a type of skin cancer) that has been confirmed by a lab test, and your melanoma started on the skin or from an unknown location
- Your doctor has recommended you receive an immune therapy treatment called nivolumab or pembrolizumab (these are anti-PD-1 treatments)
- You have health/social insurance coverage
- You are willing to sign a consent form agreeing to take part in the trial
Who may not be able to join:
- You are under 18 years of age
- Your melanoma started in the eye or in the moist lining of the body (such as the mouth, nose, or genitals)
- You have severe claustrophobia or uncontrolled diabetes, as these may prevent you from having a PET CT scan (a type of full-body imaging test)
- The only signs of your cancer spreading in the body are very small spots (less than 8mm), except if those spots are in the lungs
- You have tested positive for HIV, hepatitis C, or hepatitis B, or you have an active condition where your immune system attacks your own body
- You are not willing to sign or have withdrawn your agreement to take part
- The spread of your cancer to other parts of the body has not been confirmed by a lab test
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Micheline RAZZOUK-CADET, MD, Centre Hospitalier Universitaire de Nice
Phone: +33492035671
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Quantifying changes in FDG uptake according to PERCIST criteria:Single-lesion analysis; Quantifying changes in FDG uptake according to PERCIST criteria: Five lesion analysis; Determine the number of lesions
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.